Boehringer Ingelheim International Gmbh

Boehringer Ingelheim (canada) Ltd.

Gilead Sciences, Inc.

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Murray D Bailey

Montse Llinas-Brunet

Teddy Halmos

Nathalie Goudreau

Elise Ghiro

Jean Rancourt

Youla S Tsantrizos

Marc-Andre Poupart

Dominik M Wernic

Anne-Marie Faucher

Dale R Cameron

Bruno Simoneau

Lee Fader

Francois Bilodeau

Rebekah J Carson

Punit R Bhardwaj

Stephen Kawai

Pasquale Forgione

Sebastien Morin

Mathieu Parisien

Carl Thibeault

Marc-André Poupart

Sylvie Goulet

Serge R Landry

Simon Surprenant

Vida J Gorys

Josee Bordeleau

Pierre Louis Beaulieu

Christiane Yoakim

Cédrickx Godbout

Martin Poirier

Julie Naud

André Giroux

Steven LaPlante

Rene Coulombe

Dale Cameron

Marc-Andr&eacute; Poupart

Olivier Lepage

Steven R Laplante

Elisia Villemure

Benoît Moreau

Gulrez Fazal

Christian Brochu

Paul John Edwards

Pierre Lavallee

Maude A Poirier

Oliver Hucke

Araz Jakalian

Ellse Ghiro

Punit K Bhardwaj

William Ogilvie

François Bilodeau

Steven Laplantea

Punit-Kumar Bhardwaj

Mélissa Leblanc

Marc-André Joly

Maude Poirier

Paul J Edwards

René Coulombe

Sébastien Morin

Compounds of Formula (I) wherein n, m, R, R, R, R, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Cytomegalovirus inhibitor compounds

Compounds of Formula (I) wherein n, A, R, R, Rand Rare defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Compounds of formula I: wherein a, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Inhibitors of human immunodeficiency virus replication

Compounds of formula I: wherein R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Compounds of formula (I): wherein c, X, Y, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Compounds of formula I: wherein c, R, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Compounds of formula (I): wherein B, X, R, L, L, L, R, Rand Rare defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compounds

Racemates, diastereoisomers and optical isomers of a compound of formula (I):wherein

Hepatitis C inhibitor tri-peptides

Compounds of formula (I):  wherein R, R, R, R, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Hepatitis C inhibitor dipeptide analogs

Compounds of formula (I): wherein R, R, X, R, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.

Macrocyclic peptides active against the hepatitis C virus

Racemates, diastereolsomers and optical isomers of a compound of formula (I):wherein B is H, a Cor Caryl, Caralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with Calkyl; Calkoxy; Calkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with Calkyl; amido; or (lower alkyl)amide; or

Growing community of inventors

Pierrefonds, Canada

Murray D Bailey